Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286638, an indenopyrazole-derived CDKI with Ki-nanomolar activity against transcriptional CDKs. We examined RGB-286638's mode-of-action in MM cell lines with wild-type (wt)-p53 and those expressing mutant p53. RGB-286638 treatment resulted in MM cytotoxicity in vitro associated with inhibition of MM tumor growth and prolonged survival in vivo. RGB-286638 displayed caspase-dependent apoptosis in both wt-p53 and mutant-p53 cells that was closely associated with the downregulation of RNA polymerase II phosphorylation and inhibition of transcription. RGB-286638 triggered p53 accumulation via nucleolar stress and loss of Mdm2, accompanied by induction of p53 DNA-binding activity. In addition, RGB-286638 mediated p53-independent activity, which was confirmed by cytotoxicity in p53-knockdown and p53-mutant cells. We also demonstrated downregulation of oncogenic miR-19, miR-92a-1 and miR-21. Our data provide the rationale for the development of transcriptional CDKIs as therapeutic agents, which activate p53 in competent cells, while circumventing p53 deficiency through alternative p53-independent cell death mechanisms in p53-mutant/deleted cells.
INTRODUCTION
Cyclin-dependent kinases (CDKs) are a family of protein kinases that, upon activation by their regulatory cyclin partners, co-ordinate two main cellular processes which are indispensable for the malignant cell phenotype: cell cycle and transcription. 1 CDKs 1, 2, 3, 4 and 6 are key regulators of cell cycle progression. 2 CDKs 4 and 6, complexed with cyclin D, initiate G1 phase-specific transcription by phosphorylating the Rb protein, whereas CDK2/cyclin A promotes DNA replication during S phase, and CDK1/cyclin B regulates mitosis. CDKs 1, 2, 7, 8, 9 and 11 share important functions in mRNA transcription and have all been implicated in the phosphorylation of the Ser residues at positions 2 (S 2 ) and 5 (S 5 ) of the C-terminal domain of the largest RNA polymerase II (RNAPII) subunit essential to RNAPII transcriptional activity. 3 Unlike other CDKs, CDK9 appears to function exclusively on transcriptional regulation, phosphorylates both RNAPII S 2 and S 5 and is critical for transcription elongation of most protein coding genes, including key developmental and stimulus-responsive genes. 4 The rationale for targeting CDKs and/or cyclins in multiple myeloma (MM) originated from comprehensive cytogenetic studies suggesting that dysregulated and/or increased expression of cyclin D1, D2 or D3 occurs as an early, unifying event in MM pathogenesis, predisposing MM cells to proliferative stimuli. [5] [6] [7] In MM, specific inhibition of CDK4/6 by PD 0332991 has demonstrated only growth arrest. 8 Effective MM cytotoxicity was best achieved when multiple CDKs were inhibited concurrently, as with multi-targeted CDK inhibitors (CDKIs) such as Seliciclib, 9 UCN-01, P276-00 10 and AT7519. 11 In addition to their effect against cell cycle-specific cyclins and CDKs, these drugs target transcriptional CDKs, thereby resulting in inhibition/inactivation of RNAPII.
The primary events of RNAPII inactivation in cells are induction of p53 and decreased expression of a number of highly expressed anti-apoptotic proteins with a short half-life such as Mcl-1, survivin and XIAP. [12] [13] [14] This may result in both p53-dependent and -independent apoptosis. In MM, p53 deletion has been reported in 10% of newly diagnosed MM tumors, whereas the prevalence is much higher in advanced and extramedullary tumors, and associates with a very poor prognosis. 15, 16 Hence, CDKIs with activity against transcriptional CDKs, which activate p53 in competent cells, while circumventing p53 deficiency through alternative p53-independent cell death mechanisms in p53-mutant/deleted cells are particularly appealing for the treatment of MM.
We examined the anti-MM activity of RGB-286638, a novel compound of the indenopyrazole family of CDKIs with potent cellular activity against transcriptional-type CDKs in MM cells. RGB-286638-mediated RNAPII inhibition, induced p53 accumulation and triggered cytotoxicity in both wild-type (wt)-and mutated-p53 MM cell lines, prompting us to examine RGB-286638's mechanism of action in MM cells-expressing wt-p53 versus p53-deficient cells.
MATERIALS AND METHODS

Cell culture
Dex-sensitive (MM.1S) and -resistant (MM.1R) cells were provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA); H929, RPMI (Roswell Park Memorial Institute medium)-8226 and U266 were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA); OPM1 plasma cell leukemia cells were provided by Dr E Thompson (University of Texas Medical Branch, Galveston, TX, USA). All MM cell lines were cultured in RPMI-1640 containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Patient MM primary tumor cells were obtained from bone marrow (BM) aspirates in accordance with the Declaration of Helsinki and with the approval of the Institutional Review Board of Massachusetts General Hospital. BM mononuclear cells were separated using Ficoll-Hipaque density sedimentation, and plasma cells were purified by positive selection with anti-CD138 magneticactivated cell separation microbeads (Miltenyi Biotec, San Diego, CA, USA). BM stroma cells (BMSCs) were generated from BM specimens from MM patients as described previously. 17 Blood samples collected from healthy volunteers were processed by Ficoll-Hipaque gradient to obtain peripheral blood mononuclear cells.
RGB-286638
RGB-286638 was obtained from Agennix USA Inc, Princeton, NJ, USA. For the in vitro experiments, the drug was provided in 20 mg/ml aqueous solution.
5,6-Dichloro-1-D-ribofuranosylbenzimidazole (DRB)
DRB was obtained from Sigma-Aldrich, St Louis, MO, USA.
Cell viability assay
Colorimetric assays were performed to assay drug activity at increasing concentrations of RGB-286638. Cells from 24-or 48-h cultures were pulsed with 10 ml of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International Inc, Temecula, CA, USA) to each well, followed by incubation at 37 1C for 4 h and addition of 100 ml isopropanol containing 0.04 HCl. Absorbance readings at a wavelength of 570 nm (with correction using readings at 630 nm) were taken on a spectrophotometer (Molecular Devices Corp, Sunnyvale, CA, USA). All experiments were performed in triplicate.
Western blotting MM cells were treated with RGB-286638 and harvested; whole-cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA), as described previously. 10 Immunoblotting was performed using specific antibodies: anti-phosphorylated (p)-RNAPII S 2 , -p-RNAPII S 5 and -RNAPII (8WG16) (Covance, Princeton, NJ, USA); anti-p-Rb S 807/811
, -CDK1, -CDK4, -Cyclin D1, -CDK6, -Cyclin D3, -CDK2, -XIAP, -cleaved caspase 8, 9 and 3, -PARP (Cell Signaling Technology, Beverly, MA, USA); as well as anti-p-ERK1/2, -Cyclin B1, -Cyclin E, -Cyclin A, -Mcl-1, -p53 (DO-1), -Mdm2 (Santa Cruz Biotech, Santa Cruz, CA, USA). Blots were reprobed with the anti-actin (Santa Cruz Biotech), anti-tubulin or -GAPDH (Cell Signaling Technology) antibodies for equal protein controls.
Cell cycle analysis MM.1S cells (1 Â 10 6 ) cultured in media alone, or with 50 nM RGB-286638, were washed with ice-cold phosphate-buffered saline, fixed with 100% ethanol for 1 h at 4 1C and pretreated with RNase, DNase-free (Roche Diagnostics Corporation, Indianapolis, IN, USA) for 30 min at 37 1C. Cells were stained with propidium iodide (PI) (5 g/ml; Sigma Chemical), and cell cycle profile was determined using the BD Diva software on BD LFR2 flow cytometer (San Jose, CA, USA). Analysis of the data was done using ModFit cell cycle analysis program.
Detection of apoptosis
Apoptosis detection was performed with the annexin V-PI detection kit (Immunotech/Beckman Coulter, Miami, FL, USA). MM.1S cells (1 Â 10 6 ) were exposed for 12-24 h to RGB-286638 (50 nM). Cells were then incubated with annexin V-fluorescein isothiocyanate and PI for 15 min. Annexin V þ PI þ -positive apoptotic cells were enumerated using BD LFR2 flow cytometer (San Jose, CA, USA).
MM xenograft murine model
The in vivo anti-MM activity of RGB-286638 was evaluated in a previously established MM xenograft model. 10 RGB-286638 dosing solutions of 2 and 3 mg/ml in 5% dextrose/water (D5W) pH5.2, as well as D5W pH5.2 for vehicle-control dosing group, were prepared and provided by Agennix AG. CB-17 severe combined immunodeficient mice (Charles River Laboratories, Wilmington, MA, USA) were monitored in the Animal Research Facility at Dana-Farber Cancer Institute (DFCI) and subjected to studies approved by the Animal Ethics Committee. Forty male 5-6 week-old mice were irradiated (2 Gy (200 rad)) using cesium 137 (137Cs)-irradiator source); 24 h after irradiation, 2.5 Â 10 6 MM.1S cells were inoculated subcutaneously in the upper back. When tumor weight was B100 mg, the mice were randomly assigned into three cohorts receiving daily IV tail vein injections for 5 consecutive days with either RGB-286638 30 mg/kg (8 mice), 40 mg/kg (9 mice) or control vehicle alone (10 mice). Animals were monitored for body weight and tumor volume by caliper measurements every alternate day. Tumor volume was estimated using the following formula: ½ Â (length) Â (width).
2 Animals were euthanized in accordance with DFCI Animal Care and Use Committee guidelines by CO 2 inhalation in the event of tumor size42 cm or due to tumor ulceration. The survival was evaluated from the first day of treatment until death. Tumor growth was evaluated using caliper measurements from the first day of treatment until the day the animals were killed. Percentage of tumor growth inhibition was calculated as tumor growth inhibition on day X ¼ 100 À T/C% on day X. Log10 cell kill was calculated by the formula log10 cell kill ¼ (tumor growth delay (day)) Â (tumor doubling time (day) Â 3.32). DNA synthesis assay DNA synthesis was measured using tritiated thymidine uptake ( 3 H-TdR) (Perkin Elmer, Boston, MA, USA) as previously described. 10, 18 MM.1S cells (2-3 Â 10 3 cells/well) were incubated alone or with BMSCs in 96-well culture plates, with varying concentrations of RGB-286638 for 24-or 48-h at 37 1C. Cells were pulsed with ( 3 H-TdR) (0.5 mCi per well) during the last 8 h of the end time point, harvested with an automatic cell harvester (Cambridge Technology), and counted by using the LKB Betaplate scintillation counter (Wallac). All experiments were performed in triplicate.
RNA synthesis assay
RNA extraction
For microRNA (miRNA) expression profiling, MM.1S cells alone or in coculture with BMSCs were incubated for 8 h in control media or RGB-286638 (50 nM). Similarly, MM.1S, OPM1, U266 and RPMI cells were cultured 8 h in media alone or 50 nM RGB-286638 for miRNA-specific assays. Total RNA was extracted from MM cell pellets using mirVana miRNA Isolation Kit (Ambion Inc, Austin, TX, USA), according to the manufacturer's protocol.
miRNA expression profiling using human TaqMan low-density array cards miRNA expression profiling was performed on MM.1S cells cultured for 8 h in control media or 50 nM RGB-286638, with or without BMSCs. TaqMan low-density array using human miRNA version 2.0A and version 3.0B cards (Applied Biosystems, Foster City, CA, USA) was applied to examine the global change in miRNA expression levels in MM.1S cells when cocultured RGB-286638 P53-independent anti-MM activity D Cirstea et al with BMSCs, with or without RGB-286638 treatment. A total of 756 mature miRNA updated in the Sanger miRBase v.15.0 were quantified, as previously described. 19, 20 miRNAs with Ct values higher than 35 were excluded from the analysis. Normalization was carried out with the mean of RNU44 and RNU48. Relative quantification of miRNA expression was calculated with the 2 À DDCt Ct method using the ddCt program.
Real-time PCR detection and quantification of specific miRNA
To evaluate miR-19, miR-92a-1 and miR-21 expression levels in p53-wt MM.1S along with p53-mutated U266, RPMI, OPM1 cells with or without 8 h RGB-286638 (50 nM) treatment, we used target-specific TaqMan MicroRNA Assays (Applied Biosystems), in accordance with the manufacturer's protocol. The 2 À DDCt method was used to calculate relative changes in miRNA expression. The results were normalized to levels of miRNA endogenous control (RNU48-001006).
Nucleolar segregation analysis
Nucleolar segregation analysis was performed using the Total Nuclear-ID Red/Green Nucleolar/Nuclear Detection Kit (Enzo Life Sciences International Inc; Plymouth Meeting, PA, USA). Pretreated with RGB-286638 (50 nM) for 3 h, MM.1S cells were then incubated with 100 ml Dual Detection Reagent for 30 min at 37 1C. Live-stained cells were analyzed by immunofluorescence microscopy ( Â 60 magnification) using a standard fluorescein isothiocyanate filter set for imaging the nucleolus, and a standard Texas Red filter set for the counterstained nucleus.
Sequence-specific P53 DNA-binding assay Detection of p53 sequence-specific DNA-binding activity was performed using the p53 Transcription Factor Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) according to the manufacture's protocol. Nuclear proteins were isolated from MM.1S cells treated with 50 nM RGB-286638 for 1, 4 and 8 h using Nuclear Extraction Kit (Affymetrix Inc, Santa Clara, CA, USA). Nuclear protein aliquots were added to the 96-well plate coated with specific double-stranded DNA sequence containing the p53 response element for overnight incubation. p53 in the nuclear extract was detected by addition of a specific primary antibody directed against p53. A secondary antibody conjugated to horseradish peroxidase was added to provide a sensitive colorimetric readout at 450 nm. All experiments were performed in triplicate.
NAD þ /NADH assay NAD þ /NADH quantification assay (BioVision, Mountain View, CA, USA) was performed in MM.1S cultured with RGB-286638 (50 nM). A total of 5 Â 10 5 cells were used for the NAD þ /NADH extraction. Duplicates of extracted samples (50 ml) were transferred into a 96-well plate and incubated at room temperature for 5 min with 100 ml of NAD Cycling Mix to allow the conversion of NAD þ to NADH. The extracted solution (200 ml) from each sample was heated at 60 1C for 30 min for NAD þ decomposition. Duplicates of each NADH sample (50 ml) were transferred to a 96-well plate, 10 ml/well NADH developing solution was added; after 40 min in the dark, the plate was read at 450 nm wavelength on a microplate reader. The ratio of NAD þ /NADH was calculated as follows: (NADt À NADH)/NADH.
Lentivirus-mediated knockdown of p53
Lentiviral particles expressing short hairpin RNA against human TP53 gene (clone name NM_000546.x-941s1c, targeted sequence 5 0 -CACCATCCACTA CAACTACAT-3 0 ) were obtained from the Broad Institute (MIT, Boston, MA, USA) and transduced according to the manufacturer's protocol. Briefly, supernatants containing shTP53 or empty vector lentiviral particles were added to exponentially growing MM.1S in media containing polybrene (8 mg/ml). Fresh medium was supplemented at 24 h after infection. The infectivity was determined after 72 h by comparing the differential sensitivity to puromycin (2 mg/ml) treatment between parental and transduced cells, as assessed using MTT assay.
RESULTS
RGB-286638 demonstrated potent activity against transcriptional CDKs in MM cell lines and inhibited myeloma cell growth in vitro
To assess RGB-286638's potential anti-MM activity, we first investigated the in vitro effects of RGB-286638 treatment in MM cell lines and primary tumor cells from MM patients. RGB-286638 is a novel compound of the indenopyrazole family of CDKIs (Figure 1a ) that inhibited the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3 and p35-CDK5 (IC50, 1, 2, 3, 4 and 5 nM, respectively), and was less potent against cyclin H-CDK7 and cyclin D3-CDK6, as demonstrated by in vitro kinase profiling. 21 In addition, RGB-286638 inhibited several tyrosine and serine/threonine non-CDK enzymes, that is, GSK-3b, TAK1, AMPK, Jak2 and MEK1 (Table 1) . We investigated the dose-and time-dependent effect of treatment with RGB-286638 (12.5-100 nM) on the growth of human p53-wt (MM.1S, MM.1R and H929) and p53-mutant (U266, OPM1 and RPMI) MM cells using MTT assay, assessing viability at 24 and 48 h. The half-maximally effective concentrations (EC50) ranged between 20 and 70 nM at 48 h. Dose-dependent differences in growth among p53-wt and -mutant cells were observed after 50 nM treatment, with p53-wt MM.1S, MM.1R and H929 being slightly more sensitive to RGB-286638 treatment at 48 h (Figure 1b) . Moreover, RGB-286638 demonstrated equimolar (50 nM) activity in freshly isolated tumor cells from MM patients while manifesting less cytotoxicity in healthy donor peripheral blood mononuclear cells (Supplementary Figure S1) Figure S2) . Immunoblot analysis of MM cell lines treated with 50 nM RGB-286638 revealed increased phosphorylation of the a subunit of GSK3 at Ser, 21 Figure S2-C) . We also evaluated RGB-286638 effects on JAK2 (Janus kinase 2) and mitogenactivated protein kinase signaling by examining p-STAT3 S 727 and p-ERK1/2 in cells exposed to increasing concentrations of RGB-286638 for 4 h (Supplementary Figure S2-A) . RGB-286638 treatment did not affect STAT3 S 727 . Moreover, short exposure to RGB-286638 resulted in upregulated p-ERK1/2 in MM.1R, H929 and U266 cells.
RGB-286638-induced apoptosis in vitro translated to anti-MM activity in vivo We next examined the molecular mechanisms underlying RGB-286638-mediated cytotoxicity in p53-wt (MM.1S) and p53-mutant (U266) cells, specifically examining the effects on cell cycle-related proteins and apoptosis. Time-course immunoblot analysis revealed that 50 nM RGB-286638 treatment decreased cyclins (A, B1, D1 and D3), CDK1 and CDK4 expression levels in MM.1S cells, and reduced cyclin A and D1 levels slightly in U266 cells within 8 h (Figure 2a (Figure 3a) , and as phosphorylation of the C-terminal domain of RNAPII by CDK9/cyclin T is required for transcriptional elongation, 22, 23 we assessed the rate of RNA synthesis. Two hours of RGB-286638 (50 nM or 100 nM) treatment reduced RNA synthesis by 50% (Figure 3a) . As the BM microenvironment induces transcription and proliferation in MM cells, 24, 25 we next examined the effect of treatment on the rate of RNA and DNA synthesis in MM.1S cells, alone or cultured with patient-derived BMSCs. Using RNA synthesis assay, we found that RGB-286638 reduced the total level of transcripts in BMSCs-stimulated MM.1S cells by B50% at 8 h, and ultimately blocked transcription at 24 h (Figure 3b) , associated with marked (60%) reduction in DNA synthesis at 8 h and complete block of MM.1S proliferation at 24 h (Figure 3c ).
RGB-286638 triggered stabilization and activation of p53
As RGB-286638 inhibited transcription, and as transcriptional inhibitors can induce p53 accumulation via reduction in Mdm2 expression, we next examined effects of RGB-286638 on p53 and 6 MM.1S cells in 100 ul RPMI medium. Tumor-bearing mice were randomly assigned into three cohorts receiving daily IV tail vein injections for 5 consecutive days with 30 mg/kg or 40 mg/kg RGB-286638 or with control vehicle alone. RGB-286638 treatment resulted in tumor growth inhibition. Transient weight loss, with maximum body weight loss on day 5 (8.4%) after 30 mg/kg and on day 15 (9.9%) after 40 mg/kg dosing, was followed by recovery in the following 2 weeks. Prolonged survival was observed in both 30 mg/kg and 40 mg/kg dosing groups.
Mdm2 expression in MM cells. Time-course western blot analysis of p53-wt (MM.1S, MM.1R, H929) and p53-mutated (U266, OPM1 and RPMI) MM cells treated with 50 nM RGB-286638 showed decreased Mdm2 expression in all cell lines, associated with upregulated p-p53 S 15 and p53 levels in p53-wt, but not in p53-mutated cell lines (Figure 4a ). We next compared the effects of RGB-286638 with the previously described transcription inhibitor DRB on p53 and Mdm2 expression. Similar to RGB-286638, DRB (2 h) significantly inhibited RNA synthesis in MM.1S cells (Supplementary Figure S3) . Western blot studies of MM.1S treated with increasing concentrations of RGB-286638 or DRB for 2 h triggered p53 accumulation without affecting Mdm2 levels at doses that inhibited RNAPII phosphorylation and reduced transcription (Figure 4b) .
Previous studies linked nucleolar stress and transcriptional arrest to p53 accumulation. Specifically, transcriptional arrest due to RNA polymerase dephosphorylation triggers nucleolar reorganization and nucleolar segregation. 26 Immunofluorescence microscopy revealed that the nucleoli (green staining) of cells exposed to 3 h RGB-286638 treatment formed numerous speckles of fluorescence spread all over the nucleus (red staining), suggesting nucleolar segregation (Figure 4c ). Relocalization of nucleolar compartments during segregation is an energydependent repositioning process. 27 We therefore investigated whether RGB-286638 treatment affected the status of nicotinamide nucleotides (NAD/NADH), markers of energy transforming processes. By NADt/NADH quantification assay, RGB-286638 treatment resulted in 30% NADt/50% NADH depletion (Supplementary Figure S4) . Western blot analysis of nuclear and cytoplasmic extracts from RGB-286638-treated MM.1S cells showed accumulation of p-p53 S 15 and total p53 predominantly in the nuclear compartment (Figure 4d) .
We next examined whether p53 stabilization associated with p53 activation in RGB-286638-treated MM.1S cells. Increased p53 transcriptional activity via enhanced sequence-specific DNA binding is essential to p53-dependent apoptosis. 
RGB-286638 mediated p53-independent apoptosis in MM cells
We next tested whether RGB-286638-induced cell death was independent of p53 pathway activation. Knockdown of p53 by p53-targeting short hairpin RNA lentiviral constructs rescued 14% cells from RGB-286638-induced cell death (Figure 5a) . No significant effect on p-RNAPII was observed, suggesting that RNAPII activity was independent of p53 status. P53-independent RGB-286638 activity was further validated by its cytotoxic effects in p53-mutated U266, OPM1 and RPMI MM cell lines. As measured by [5 0 -3 H]uridine incorporation, 2 h exposure to increasing doses of RGB-286638 reduced RNA synthesis in p53-mutated MM cell lines, with significant inhibition at 24 h (Figure 5b ). As expected, western blot studies of p53-mutated U266, OPM1 and RPMI cells showed that RGB-286638 treatment consistently reduced Mcl-1 levels, which preceded PARP cleavage (Figure 5c ). RGB-286638 modulated miRNA expression RNAPII is a key regulator of miRNA synthesis, and RGB-286638 treatment resulted in early and potent inhibition of RNAPII activity. Moreover, recent studies suggest a strong correlation between dysregulated miRNA and high-risk myeloma. 29, 30 We therefore next examined the effect of the BMSC-MM cell interaction on miRNA. We performed TaqMan low-density array-based miRNA expression profiling in MM.1S cells cultured for 8 h with or without BMSCs, in the presence or absence of 50 nM RGB-286638. Our data demonstrated that RGB-286638 treatment modulated BMSCs-induced miRNA expression (Supplementary Figure S5) . Among microarrays identified with significant relative quantification values, we selected miR-21-3p and miR-19a-5p, which have been associated with tumorigenesis in MM. [31] [32] [33] Both were decreased in MM.1S cells in culture with BMSCs after RGB-286638 treatment as confirmed by miR-21-3p and miR-19a-5p TaqMan-specific miRNA assays (Figure 6a) .
We next tested the levels of miR-21 and two members of the oncogenic cluster miR-17-92 (miR-19a and miR-92a-1) in p53-mutated MM cells after RGB-286638 treatment. We assayed U266, OPM1 and RPMI cells exposed to RGB-286638 treatment (50 nM for 8 h) using the TaqMan-specific miRNA assays for 
DISCUSSION
It is widely accepted that the diverse effects of CDKIs are due to their activity against multiple CDKs involved in both cell cycle and transcription regulation. Although most clinically evaluated CDKIs target several CDKs, it has been proposed that the induction of apoptosis arises primarily due to inhibition of transcriptional-type CDKs. 34 Inhibition of transcriptional CDKs, in particular CDK9, leads to the downregulation of transcriptionally inducible genes with short half-lives, including cell cycle regulators and anti-apoptotic factors. 35 Our study found CDK9 to be among the primary targets of RGB-286638 mediating its pro-apoptotic activity in MM cells. In vitro kinase assays showed that RGB-286638 is a potent inhibitor of CDK 1, 2, 3, 4, 5 and 9, as well as 44-and 55-fold less active against CDK 7 and 6, respectively. Kinase profiling of RGB-286638 identified additional inhibition of distinct serine/threonine and tyrosine protein kinases, predicting modulation of GSK3, STAT3 and mitogen-activated protein kinase signaling. In MM cells, however, RGB-286638 demonstrated preferential inhibition of CDK9 over other targets. The IC50 of RGB-286638 inhibited MM cell proliferation (50-100 nM) and dephosphorylated RNAPII S 2 /S 5 , but did not modulate phosphorylation of Rb, STAT3 and ERK1/2 proteins. We noted that p-Rb S 780 site, which is phosphorylated by several kinases including cyclin D-dependent kinases, was not affected by RGB-286638 treatment. Importantly, S 807/811 phosphorylation of Rb was targeted by RGB-286638 in MM.1S and MM.1R cells. Recent evidence suggests that physical interaction between CDK9 and Rb is associated with CDK9-mediated phosphorylation of Rb on its C-terminus 793-928 ; 36 therefore, RGB-286638-mediated inhibition of p-Rb S 807/811 may be triggered by inhibition of CDK9 activity. These findings, together with RGB-286638-induced transcriptional arrest and caspasedependent apoptosis in MM cell lines, suggest that inhibition of transcriptional CDK, in particular CDK9, is the primary mechanism of action of RGB-286638 in MM cells.
Inhibition of RNAPII-mediated transcription was among the early cellular responses that we detected after RGB-286638 treatment. The blockade of RNA synthesis has been proposed to be an inducer of p53 accumulation. 12 In our study, RGB-286638 treatment increased p53 levels in MM cells in a manner similar to the transcriptional inhibitor DRB. However, the exact molecular mechanisms of inhibited RNAPII and blocked transcription leading to p53 protein stabilization remain unclear. An important trigger seems to be the reduction in Mdm2 mRNA and protein levels. 37 Normally, p53 expression is kept low mainly by interactions with its major regulator Mdm2, which serves as an E3 ubiquitin ligase for p53 and targets p53 for degradation via the 26S proteasome. Hence, depletion of Mdm2 inevitably leads to p53 stabilization and accumulation. We, however, found that RGB-286638-mediated RNAPII inhibition was associated with increased p53 expression before Mdm2 was downregulated, consistent with studies showing that blockade of transcription can induce nuclear accumulation of p53 without downregulation of Mdm2 levels. 38 Specifically, nucleolar fragmentation significantly reduces the levels of 45S precursor ribosomal RNA, leading to increased cellular levels of free ribosomal proteins, some of which (RPL5, RPL11 and RPL23) then bind to the central regulatory domain of Mdm2 protein and inhibit Mdm2-mediated p53 degradation. [39] [40] [41] Taken together with our findings that RGB-286638 treatment induced nucleolar fragmentation, we suggest that nucleolar stress and depletion of Mdm2, both mediated through transcriptional arrest, may contribute to p53 induction in MM cells.
The role of p53 induction in the apoptotic response to CDKIs is controversial. In our study, RGB-286638-induced p53 nuclear accumulation associated with increased p53 DNA-binding activity. Increased p53 transcriptional activity via enhanced sequencespecific DNA binding is essential to p53-dependent apoptosis. 28 In fact, p53 knockdown rescued 14% cells from RGB-286638-mediated cell death, suggesting that p53 had a role in RGB-286638 cytotoxicity. That may in part explain the observed differential response to RGB-286638 between p53-wt and p53-mutant cell lines.
In addition, RGB-286638 displayed p53-independent cytotoxicity and caspase-dependent apoptosis induction in p53-mutant cells were closely associated with downregulation of RNAPII phosphorylation and inhibition of transcription. RNAPII's control over miRNA transcription, together with recent findings that miR-19, miR-92a-1 and miR-21 miRNAs have a role in MM tumorigenesis, prompted us to examine effects of RGB-286638 on the expression of these miRNAs. Our data show downregulation of oncogenic miR-19, miR-92a-1 and miR-21 associated with reduced expression of Mcl-1 following RNAPII transcriptional arrest in U266 and OPM1 p53-mutant cells, suggesting a contributory effect to p53-independent MM cytotoxicity.
In conclusion, our data provide the rationale for the development of transcriptional CDKIs as anti-MM agents that activate p53 in competent cells, while circumventing p53 deficiency through alternative p53-independent cell death mechanisms in p53-mutant/deleted cells. 
